Abiomed (NASDAQ:ABMD) is scheduled to announce Q3 earnings results on Thursday, February 6th, before market open.
The consensus EPS Estimate is $1.09 (+12.4% Y/Y) and the consensus Revenue Estimate is $226.92M (+13.1% Y/Y).
Over the last 2 years, ABMD has beaten EPS estimates 100% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. Revenue estimates have seen 1 upward revision and 0 downward.